Wegovy (Semaglutide 2.4 mg) and Diarrhea: When to Call the Doctor

How often does diarrhea happen on Wegovy 2.4 mg?

In the three pooled placebo-controlled trials behind the Wegovy label — 2,116 adults on semaglutide 2.4 mg and 1,261 on placebo, treated for up to 68 weeks — diarrhea was reported by 30% versus 16% [1]. That makes it the second most common adverse reaction after nausea (44% versus 16%) [1]. Diarrhea was also the third most common reaction leading to permanent discontinuation: 0.7% versus 0.1%, behind nausea (1.8% versus 0.2%) and vomiting (1.2% versus 0%) [1]. Overall, 6.8% of people on Wegovy and 3.2% on placebo stopped treatment because of an adverse reaction of any kind [1].

Severe gastrointestinal reactions, the label's broader category, occurred in 4.1% versus 0.9% [1]. In STEP 2, a 68-week trial of 1,210 adults with type 2 diabetes, gastrointestinal adverse events of any severity were reported by 63.5% on semaglutide 2.4 mg versus 34.3% on placebo [3].

What the label flags

The label names specific situations, none of which is defined by a stool count [1].

Fluid loss and kidney injury

Wegovy carries a warning for acute kidney injury due to volume depletion, and the label says to monitor renal function in patients who report reactions that could lead to volume depletion [1]. In the trials, kidney injury occurred at 0.4 versus 0.2 cases per 100 patient-years (7 versus 4 adults); it was more common in people who already had kidney impairment, happened more often during dose titration, and often followed gastrointestinal fluid loss [1].

Persistent or severe abdominal pain

The pancreatitis warning says to observe patients after starting Wegovy for persistent or severe abdominal pain, sometimes radiating to the back, which may or may not come with nausea or vomiting, and to discontinue Wegovy if pancreatitis is suspected [1]. Confirmed pancreatitis was uncommon: 4 adults on Wegovy (0.2 cases per 100 patient-years) versus 1 on placebo [1].

Gallbladder disease

Gallstones were reported by 1.6% of adults on Wegovy injection versus 0.7% on placebo, and cholecystitis by 0.6% versus 0.2% [1]. The label says suspected gallstones need gallbladder studies and clinical follow-up [1].

Severe gastrointestinal reactions

The label warns that Wegovy is associated with gastrointestinal adverse reactions, sometimes severe, and that it is not recommended in people with severe gastroparesis [1]. Postmarketing reports listed in the label include ileus, intestinal obstruction, and severe constipation with fecal impaction [1].

Allergic reactions

Anaphylaxis and angioedema have been reported with Wegovy. The label says to discontinue the drug if a hypersensitivity reaction is suspected and to promptly seek medical advice [1].

Is there a set number of days or stools?

The Wegovy label does not set a number of days or loose stools for seeking help [1]. Its flagged situations are the ones above.

The titration schedule is 0.25 mg for weeks 1 to 4, 0.5 mg for weeks 5 to 8, 1 mg for weeks 9 to 12, 1.7 mg for weeks 13 to 16, then maintenance at 1.7 mg or 2.4 mg [1]. An April 2024 version of the label says to follow that schedule to minimize gastrointestinal adverse reactions, and that if a dose is not tolerated during escalation, consider delaying escalation by 4 weeks [2]. The current label lists 1.7 mg as an adult maintenance dose alongside 2.4 mg [1].

We found no study that measured how long individual diarrhea episodes last in people taking semaglutide 2.4 mg. The trials report how often diarrhea occurred, not how long an episode lasted.